Journal of Pain and Symptom Management
Volume 25, Issue 1 , Pages 38-47 , January 2003

Driving Ability Under Long-Term Treatment with Transdermal Fentanyl

  • Rainer Sabatowski, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Rainer Sabatowski, MD, Pain Clinic, Department of Anesthesiology, University of Cologne, 50924 Cologne, Germany
    • Department of Anesthesiology, University of Cologne, Cologne, Germany
    • ,
  • Susanne Schwalen, MD

      Affiliations

    • Medical Affairs Department, Janssen-Cilag GmbH, Neuss, Germany
    • ,
  • Klaus Rettig, MS

      Affiliations

    • Bureau of Evaluation and Quality Assurance in Medicine, Meerbusch, Germany
    • ,
  • Klaus W Herberg, MD

      Affiliations

    • Technischer Überwachungsverein GmbH, Cologne, Germany
    • ,
  • Stephan M Kasper, MD

      Affiliations

    • Department of Anesthesiology, University of Cologne, Cologne, Germany
    • ,
  • Lukas Radbruch, MD

      Affiliations

    • Department of Anesthesiology, University of Cologne, Cologne, Germany

,Accepted 25 February 2002.

References 

  1. Portenoy RK. Current pharmacotherapy of chronic pain. J Pain Symptom Manage. 2000;19:S16–S20
  2. Savage SR. Opioid use in the management of chronic pain. Med Clin North Am. 1999;83:761–786
  3. Portenoy RK. Tolerance to opioid analgesics (clinical aspects). Cancer Surv. 1994;21:49–65
  4. Bruera E, Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain. 1989;39:13–16
  5. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 1995;10:378–384
  6. Banning A, Sjogren P. Cerebral effects of long-term oral opioids in cancer patients measured by continuous reaction time. Clin J Pain. 1990;6:91–95
  7. Sjogren P, Thomsen AB, Olsen AK. Impaired neuropsychological performance in chronic nonmalignant pain patients receiving long-term oral opioid therapy. J Pain Symptom Manage. 2000;19:100–108
  8. Vainio A, Ollila J, Matikainen E, et al.  Driving ability in cancer patients receiving long-term morphine analgesia. Lancet. 1995;346:667–670
  9. Larsen B, Otto H, Dorscheid E, Larsen R. [Effects of long-term opioid therapy on psychomotor function in patients with cancer pain or non-malignant pain]. Anaesthesist 1999;48:613–624.
  10. Hanks GW, O'Neill WM, Simpson P, Wesnes K. The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects. Eur J Clin Pharmacol. 1995;48:455–460
  11. Galski T, Williams JB, Ehle HT. Effects of opioids on driving ability. J Pain Symptom Manage. 2000;19:200–208
  12. Schneider U, Bevilacqua C, Jacobs R, et al.  Effects of fentanyl and low doses of alcohol on neuropsychological performance in healthy subjects. Neuropsychobiology. 1999;39:38–43
  13. Stevenson GW, Pathria MN, Lamping DL, et al.  Driving ability after intravenous fentanyl or diazepam. A controlled double-blind study. Invest Radiol. 1986;21:717–719
  14. Zacny JP, Lichtor JL, Zaragoza JG, de Wit H. Subjective and behavioral responses to intravenous fentanyl in healthy volunteers. Psychopharmacology (Berl). 1992;107:319–326
  15. Thapar P, Zacny JP, Thompson W, Apfelbaum JL. Using alcohol as a standard to assess the degree of impairment induced by sedative and analgesic drugs used in ambulatory surgery. Anesthesiology. 1995;82:53–59
  16. Veselis RA, Reinsel RA, Feshchenko VA, et al.  Impaired memory and behavioral performance with fentanyl at low plasma concentrations. Anesth Analg. 1994;79:952–960
  17. Dellemijn PL, van Duijn H, Vanneste JA. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage. 1998;16:220–229
  18. Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage. 1998;15:168–175
  19. Nugent M, Davis C, Brooks D, Ahmedzai S. Long-term observations of patients receiving transdermal fentanyl after a randomized trial. J Pain Symptom Manage. 2001;21:385–391
  20. Radbruch L, Sabatowski R, Petzke F, et al.  Transdermal fentanyl for the management of cancer pain—a survey of 1005 patients. Pall Med. 2001;15:309–321
  21. Herberg K. Untersuchung der Entwicklung der sicherheitsrelevanten Leistungsfähigkeit mit dem Lebensalter, 2 ed. Köln: TÜV Kraftfahrt GmbH—Institut für Verkehrssicherheit; 1998;
  22. Herberg KW. Entwicklung der sicherheitsrelevanten Leistungsfähigkeit mit dem Lebensalter. Euro J Ger. 2000;2:18–26
  23. Bundesregierung D. Verordnung über die Zulassung von Personen zum Strassenverkehr und zur Änderung strassenverkehrsrechtlicher Vorschriften. Bundesgesetzblatt. 1998;55:2214–2262
  24. International Council on Alcohol Drugs and Traffic Safety. Guidelines on experimental studies undertaken to determine a medicinal drug's effect on driving or skills related to driving. 1999, Available at: www.agnp.de.
  25. Kroj G. Psychologisches Gutachten Kraftfahreignung. Deutscher Bonn: Psychologenverlag; 1995;
  26. Schuhfried GmbH, ed. Cognitrone - Handbuch. 1994, Dr. Schuhfried GmbH: Mödling.
  27. Schuhfried GmbH, ed. Wiener Determinationstest, Version 2.00. 1996, Dr. Schuhfried GmbH: Mödling.
  28. Schuhfried GmbH, ed. Zweihand-Koordination, Version 4.00. 1995, Dr. Schuhfried GmbH: Mödling.
  29. Schuhfried GmbH, ed. Vigilanz, Version 5.00. 1995, Dr. Schuhfried GmbH: Mödling.
  30. Richter R, Hobi V. [The impairment of the ability to drive with blood alcohol concentrations of 0.5 per mille. A review of the literature]. Schweiz Med Wochenschr 1975;105:884–890.
  31. Bartl G, Lager F, Domesle L. [Test performance with minimal alcoholic intoxication]. Blutalkohol 1996;33:1–16.
  32. Herberg KW. [Antidepressives and traffic safety]. Fortschr Neurol Psychiatr 1994;1:24–28.
  33. O'Brien P. Procedures for comparing samples with multiple endpoints. Biometrics. 1984;40:1079–1087
  34. Hemmelgarn B, Suissa S, Huang A, et al.  Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA. 1997;278:27–31
  35. Soyka M, Dittert S, Gartenmeier A, Schafer M. [Driving fitness in therapy with antidepressive drugs]. Versicherungsmedizin 1998;50:59–66.
  36. Lorenz J, Baumgärtner U, Zander A, Bromm B. Differenzierung von schmerz- und morphinbedingter Beeinträchtigung kognitiver Leistungen und subjektiver Befindlichkeit bei Knochenmarktransplantationspatienten. Schmerz. 1996;10:80–88
  37. Lorenz J, Beck H, Bromm B. Cognitive performance, mood and experimental pain before and during morphine-induced analgesia in patients with chronic non-malignant pain. Pain. 1997;73:369–375
  38. Zacny JP, Lichtor JL, Thapar P, et al.  Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers. J Pharmacol Exp Ther. 1994;270:579–588
  39. Zacny JP, Conley K, Galinkin J. Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J Pharmacol Exp Ther. 1997;282:1187–1197
  40. Zacny JP, Hill JL, Black ML, Sadeghi P. Comparing the subjective, psychomotor and physiological effects of intravenous pentazocine and morphine in normal volunteers. J Pharmacol Exp Ther. 1998;286:1197–1207
  41. Hill JL, Zacny JP. Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology (Berl). 2000;152:31–39
  42. Walker DJ, Zacny JP. Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. J Pharmacol Exp Ther. 1999;289:1454–1464
  43. Walker DJ, Zacny JP. Subjective, psychomotor, and analgesic effects of oral codeine and morphine in healthy volunteers. Psychopharmacology (Berl). 1998;140:191–201
  44. Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, Pappagallo M. Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage. 1998;15:185–194
  45. Strumpf M, Köhler A, Zenz M, et al.  Opioide und Fahrtüchtigkeit. Schmerz. 1997;11:233–240
  46. Schulzeck S, Maier C, Rochholz G, Schütz H. Stellenwert des “Medikamenten-Screenings” in der Therapie chronischer Schmerzen. Schmerz. 1999;13:133–137
  47. Brown SC, Glass JM, Park DC. The relationship of pain and depression to cognitive function in rheumatoid arthritis patients. Pain. 2002;96:279–284
  48. Emsbach M, Friedel B. [Traffic accidents of senior citizen car drivers]. Z Gerontol Geriatr 1999;32:318–325.
  49. Willette R, Walsh J. Drugs, driving, and traffic safety. Geneva: World Health Organization; 1983;

PII: S0885-3924(02)00539-0

Journal of Pain and Symptom Management
Volume 25, Issue 1 , Pages 38-47 , January 2003

Article Tools

* Image Usage & Resolution